AvenCell Therapeutics to Present First Phase 1 Results for Switchable Allogeneic CAR-T Therapy in AML
WATERTOWN, Massachusetts, USA & DRESDEN, Germany, June 2, 2026 AvenCell Therapeutics has announced that it will present results from...
EHA 2026
Advertisement
PeproMene Bio CAR-T Therapy Shows Durable Lymphoma Responses
IRVINE, California, May 29, 2026 PeproMene Bio, Inc. has announced that updated clinical data from its ongoing Phase 1...
Novartis Highlights New Cancer Data at ASCO & EHA 2026
BASEL, Switzerland, May 21, 2026 Novartis announced it will present more than 65 company-sponsored and investigator-sponsored abstracts at the...
Akeso Reports Positive Phase II Ligufalimab AML Data at EHA 2026
HONG KONG, May 15, 2026 Akeso, Inc. announced positive Phase II clinical trial results for ligufalimab (AK117) in frontline...
Enliven Therapeutics Reports Strong ELVN-001 CML Data
BOULDER, Colo., May 12, 2026 Enliven Therapeutics announced new positive clinical findings from its ongoing Phase 1 ENABLE trial...
Advertisement
